Cohance Lifesciences Limited Share Price & Analysis
₹445.65▼ -1.12%Updated 21 Jul 2026, 05:01 pm IST
LTP
₹445.65
-1.12%
Open
₹—
High
₹449.9
Low
₹440.7
Close
₹445.65
52W High
₹1,081
52W Low
₹267
Volume
292K
Lot Size
1
Sector
Healthcare
Market Cap
₹17K Cr
Face Value
₹1
Mid CapNIFTY 500SMALLCAP 100
Price Chart
Fundamentals
P/E
85.7
Sector P/E
54.4
P/B
4.2
EPS
₹4.68
ROE
7.04%
ROCE
8.35%
D/E Ratio
0.1
Div Yield
0%
Book Value
₹102
+
Strengths
- ✓Low debt relative to equity (D/E 0.1x)
−
Concerns
- ✗Premium to sector peers (P/E 85.7x vs industry 54.4x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
COHANCE · as of Mar 2026
Promoters50.10%
FII11.05%▲0.21
DII16.60%▼0.07
Public22.24%▼0.13
Govt0.01%
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 60.00% | 50.10% | 50.10% | 50.10% | 50.10% | 50.10% |
| FII | 10.14% | 9.54% | 9.80% | 10.70% | 10.84% | 11.05% |
| DII | 15.94% | 17.24% | 17.42% | 16.95% | 16.67% | 16.60% |
| Public | 13.93% | 23.11% | 22.67% | 22.26% | 22.37% | 22.24% |
| Govt | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
Corporate Events
Annual General Meeting
AGM5 Aug 2024
Annual General Meeting
AGM11 Dec 2023
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹619.12 Cr ▲13.7% | ₹544.55 Cr ▼2.0% | ₹555.57 Cr ▲1.1% | ₹549.31 Cr ▼34.6% | ₹840.42 Cr ▲24.3% | ₹676.23 Cr ▲12.0% | ₹603.77 Cr ▲23.7% | ₹488.08 Cr |
| Op. Profit | ₹98.68 Cr ▲3.5% | ₹95.35 Cr ▼21.2% | ₹120.95 Cr ▲8.0% | ₹112.01 Cr ▼51.1% | ₹229.22 Cr ▼3.4% | ₹237.37 Cr ▲15.6% | ₹205.37 Cr ▲64.2% | ₹125.1 Cr |
| OPM | 15.9% ▼9.0% | 17.5% ▼19.6% | 21.8% ▲6.8% | 20.4% ▼25.2% | 27.3% ▼22.3% | 35.1% ▲3.2% | 34.0% ▲32.7% | 25.6% |
| Net Profit | ₹8.31 Cr ▼71.4% | ₹29.02 Cr ▼56.3% | ₹66.39 Cr ▲43.1% | ₹46.4 Cr ▼60.4% | ₹117.15 Cr ▼23.7% | ₹153.48 Cr ▲11.0% | ₹138.24 Cr ▲83.4% | ₹75.37 Cr |
| EPS (₹) | 0.51 ▼46.9% | 0.96 ▼50.5% | 1.94 ▲51.6% | 1.28 ▼72.9% | 4.73 ▼21.3% | 6.01 ▲10.5% | 5.44 ▲83.8% | 2.96 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2.3K Cr ▲89.4% | ₹1.2K Cr ▲14.0% | ₹1.1K Cr ▼21.6% | ₹1.3K Cr ▲1.5% | ₹1.3K Cr ▲30.7% | ₹1.0K Cr ▲21.1% | ₹834 Cr ▲120.6% | ₹378 Cr |
| Expenses | ₹1.8K Cr ▲124.1% | ₹822 Cr ▲27.4% | ₹645 Cr ▼15.8% | ₹766 Cr ▲3.8% | ₹738 Cr ▲30.2% | ₹567 Cr ▲26.3% | ₹449 Cr ▲118.0% | ₹206 Cr |
| Op. Profit | ₹427 Cr ▲13.9% | ₹375 Cr ▼7.6% | ₹406 Cr ▼29.3% | ₹574 Cr ▼1.4% | ₹582 Cr ▲31.4% | ₹443 Cr ▲15.1% | ₹385 Cr ▲123.8% | ₹172 Cr |
| OPM | 19.0% ▼38.7% | 31.0% ▼20.5% | 39.0% ▼9.3% | 43.0% ▼2.3% | 44.0% ▲0.0% | 44.0% ▼4.3% | 46.0% ▲2.2% | 45.0% |
| Other Income | ₹5 Cr ▼91.4% | ₹58 Cr ▼6.5% | ₹62 Cr ▲34.8% | ₹46 Cr ▼65.4% | ₹133 Cr ▲95.6% | ₹68 Cr ▲3.0% | ₹66 Cr ▲6500.0% | ₹1 Cr |
| Interest | ₹37 Cr ▲208.3% | ₹12 Cr ▲71.4% | ₹7 Cr ▼46.2% | ₹13 Cr ▲44.4% | ₹9 Cr ▼25.0% | ₹12 Cr ▼47.8% | ₹23 Cr ▲666.7% | ₹3 Cr |
| Depreciation | ₹187 Cr ▲142.9% | ₹77 Cr ▲40.0% | ₹55 Cr ▲14.6% | ₹48 Cr ▲23.1% | ₹39 Cr ▲21.9% | ₹32 Cr ▲33.3% | ₹24 Cr ▲100.0% | ₹12 Cr |
| PBT | ₹207 Cr ▼39.8% | ₹344 Cr ▼15.3% | ₹406 Cr ▼27.5% | ₹560 Cr ▼16.2% | ₹668 Cr ▲42.7% | ₹468 Cr ▲15.6% | ₹405 Cr ▲156.3% | ₹158 Cr |
| Tax % | 27.0% ▲17.4% | 23.0% ▼11.5% | 26.0% ▼3.7% | 27.0% ▼15.6% | 32.0% ▲39.1% | 23.0% ▲4.5% | 22.0% ▼29.0% | 31.0% |
| Net Profit | ₹150 Cr ▼43.4% | ₹265 Cr ▼11.7% | ₹300 Cr ▼27.0% | ₹411 Cr ▼9.5% | ₹454 Cr ▲25.4% | ₹362 Cr ▲14.2% | ₹317 Cr ▲190.8% | ₹109 Cr |
| EPS (₹) | 4.68 ▼55.5% | 10.52 ▼10.8% | 11.8 ▼27.0% | 16.16 ▼9.4% | 17.83 ▲25.3% | 14.23 ▲14.3% | 12.45 | — |
| Div Payout | 0.0% | 0.0% | 0.0% ▼100.0% | 37.0% ▲32.1% | 28.0% ▲100.0% | 14.0% ▼30.0% | 20.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Liabilities | ||||||||
| Equity Capital | ₹38 Cr ▲52.0% | ₹25 Cr ▲0.0% | ₹25 Cr ▲0.0% | ₹25 Cr ▲0.0% | ₹25 Cr ▲0.0% | ₹25 Cr ▲92.3% | ₹13 Cr | ₹0 Cr |
| Reserves | ₹3.9K Cr ▲131.8% | ₹1.7K Cr ▼17.5% | ₹2.0K Cr ▲18.4% | ₹1.7K Cr ▲13.8% | ₹1.5K Cr ▲30.0% | ₹1.2K Cr ▲38.8% | ₹832 Cr ▲43.9% | ₹578 Cr |
| Borrowings | ₹400 Cr ▲43.4% | ₹279 Cr ▲329.2% | ₹65 Cr ▼7.1% | ₹70 Cr ▼27.8% | ₹97 Cr ▼32.2% | ₹143 Cr ▼23.1% | ₹186 Cr ▲124.1% | ₹83 Cr |
| Other Liabilities | ₹1.4K Cr ▲34.3% | ₹1.1K Cr ▲665.2% | ₹138 Cr ▼13.8% | ₹160 Cr ▼22.0% | ₹205 Cr ▲35.8% | ₹151 Cr ▲6.3% | ₹142 Cr ▲15.4% | ₹123 Cr |
| Total Liabilities | ₹5.7K Cr ▲89.0% | ₹3.0K Cr ▲34.5% | ₹2.3K Cr ▲14.6% | ₹2.0K Cr ▲7.4% | ₹1.8K Cr ▲24.2% | ₹1.5K Cr ▲25.7% | ₹1.2K Cr ▲49.8% | ₹783 Cr |
| Assets | ||||||||
| Fixed Assets | ₹3.4K Cr ▲96.9% | ₹1.7K Cr ▲155.7% | ₹670 Cr ▲1.1% | ₹663 Cr ▲24.2% | ₹534 Cr ▲21.1% | ₹441 Cr ▲23.5% | ₹357 Cr ▲31.7% | ₹271 Cr |
| CWIP | ₹173 Cr ▼32.4% | ₹256 Cr ▲43.0% | ₹179 Cr ▲8.5% | ₹165 Cr ▲450.0% | ₹30 Cr ▼68.8% | ₹96 Cr ▼5.9% | ₹102 Cr ▼8.1% | ₹111 Cr |
| Investments | ₹529 Cr ▲57.0% | ₹337 Cr ▼62.7% | ₹904 Cr ▲68.7% | ₹536 Cr ▼10.4% | ₹598 Cr ▲10.3% | ₹542 Cr ▲60.4% | ₹338 Cr ▲4728.6% | ₹7 Cr |
| Other Assets | ₹1.7K Cr ▲128.3% | ₹725 Cr ▲44.7% | ₹501 Cr ▼16.6% | ₹601 Cr ▼9.9% | ₹667 Cr ▲68.9% | ₹395 Cr ▲5.1% | ₹376 Cr ▼4.6% | ₹394 Cr |
| Total Assets | ₹5.7K Cr ▲89.0% | ₹3.0K Cr ▲34.5% | ₹2.3K Cr ▲14.6% | ₹2.0K Cr ▲7.4% | ₹1.8K Cr ▲24.2% | ₹1.5K Cr ▲25.7% | ₹1.2K Cr ▲49.8% | ₹783 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹368 Cr ▲27.8% | ₹288 Cr ▼19.6% | ₹358 Cr ▼21.7% | ₹457 Cr ▲38.5% | ₹330 Cr ▼13.8% | ₹383 Cr ▼5.9% | ₹407 Cr ▲714.0% | ₹50 Cr |
| Investing CF | ₹-255 Cr ▼0.8% | ₹-253 Cr ▲30.1% | ₹-362 Cr ▼85.6% | ₹-195 Cr ▼43.4% | ₹-136 Cr ▲56.3% | ₹-311 Cr ▲24.7% | ₹-413 Cr ▼535.4% | ₹-65 Cr |
| Financing CF | ₹-165 Cr ▼5600.0% | ₹3 Cr ▲121.4% | ₹-14 Cr ▲94.2% | ₹-242 Cr ▼55.1% | ₹-156 Cr ▼105.3% | ₹-76 Cr ▼1185.7% | ₹7 Cr ▼73.1% | ₹26 Cr |
| Net Cash Flow | ₹-51 Cr ▼234.2% | ₹38 Cr ▲311.1% | ₹-18 Cr ▼190.0% | ₹20 Cr ▼45.9% | ₹37 Cr ▲840.0% | ₹-5 Cr ▼600.0% | ₹1 Cr ▼90.9% | ₹11 Cr |
| Free Cash Flow | ₹169 Cr ▲28.0% | ₹132 Cr ▼57.0% | ₹307 Cr ▲79.5% | ₹171 Cr ▼32.9% | ₹255 Cr ▼6.3% | ₹272 Cr ▼10.5% | ₹304 Cr ▲5166.7% | ₹-6 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 110d ▲26.4% | 87d ▲89.1% | 46d ▲53.3% | 30d ▼53.8% | 65d ▲75.7% | 37d ▼27.5% | 51d ▼64.1% | 142d |
| Inventory Days | 310d ▲55.8% | 199d ▼25.7% | 268d ▼3.9% | 279d ▲7.7% | 259d ▲6.6% | 243d ▼12.6% | 278d ▼50.0% | 556d |
| Days Payable | 157d ▲63.5% | 96d ▲95.9% | 49d ▼22.2% | 63d ▼35.1% | 97d ▼3.0% | 100d ▼11.5% | 113d ▼40.5% | 190d |
| Cash Conv. Cycle | 263d ▲38.4% | 190d ▼28.3% | 265d ▲7.3% | 247d ▲8.3% | 228d ▲26.7% | 180d ▼17.1% | 217d ▼57.4% | 509d |
| Working Capital Days | 175d ▲136.5% | 74d ▼35.7% | 115d ▲16.2% | 99d ▼8.3% | 108d ▲92.9% | 56d ▼12.5% | 64d ▼68.8% | 205d |
| ROCE | 8.0% ▼46.7% | 15.0% ▼21.1% | 19.0% ▼40.6% | 32.0% ▼22.0% | 41.0% ▲2.5% | 40.0% ▼20.0% | 50.0% | — |
Source: Screener.in · Lower days = better efficiency
About Cohance Lifesciences Limited
Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling customer needs and expectations.[1]
Healthcare · Pharmaceuticals & Biotechnology
Related Analysis
Frequently Asked Questions
What is Cohance Lifesciences Limited share price today?▾
Cohance Lifesciences Limited (COHANCE) is currently trading at ₹445.65 on NSE, down 1.12% as of the last market session. Prices update daily after market close on MarketNetra.
Is Cohance Lifesciences Limited available in F&O (Futures & Options)?▾
Yes, Cohance Lifesciences Limited (COHANCE) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Cohance Lifesciences Limited 52-week high and low?▾
Cohance Lifesciences Limited's 52-week high is ₹1,081 and the 52-week low is ₹267. The current price of ₹445.65 is 58.8% below the 52W high.
What is Cohance Lifesciences Limited P/E ratio?▾
Cohance Lifesciences Limited's current P/E ratio is 85.7. This indicates the market is paying ₹85.7 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Cohance Lifesciences Limited options?▾
Cohance Lifesciences Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade COHANCE options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.